ArticleBritish journal of clinical pharmacology2011
Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.
Article in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 90 citations in OpenAlex.
- Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.Clinical interventions in aging · 2014Trial
- Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.The Journal of clinical endocrinology and metabolism · 2024Article
- Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- Inflammation and olfactory loss are associated with at least 139 medical conditions.Frontiers in molecular neuroscience · 2024Article
- Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine.Frontiers in psychiatry · 2023Article
- Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.Frontiers in oncology · 2023Article
- Spinal cord injury-induced cognitive impairment: a narrative review.Neural regeneration research · 2022Review
- A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Isotretinoin and neuropsychiatric side effects: Continued vigilance is needed.Journal of affective disorders reports · 2021Article
- Effects of chronic tramadol administration on cognitive flexibility in mice.Psychopharmacology · 2021Article
- Venlafaxine Attenuated the Cognitive and Memory Deficit in Mice Exposed to Isoflurane Alone.Frontiers in neurology · 2021Article
- Benzodiazepine-Related Cognitive Impairment or Dementia: A Signal Detection Study Using a Case/Non-Case Approach.Psychiatry investigation · 2020Article
- Leveraging digital media data for pharmacovigilance.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
- Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.British journal of clinical pharmacology · 2018Article
- Testing Claims of Crime-Related Amnesia.Frontiers in psychiatry · 2018Review
- Comparative effects of chronic administrations of gabapentin, pregabalin and baclofen on rat memory using object recognition test.Research in pharmaceutical sciences · 2017Article
- An Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity.PloS one · 2016Article
- Non-Alzheimer's disease-related memory impairment and dementia.Dialogues in clinical neuroscience · 2013Review
- Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries.European journal of clinical pharmacology · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate putative associations of reports of memory disorders and suspected drugs.
methodsWe used the case/noncase method in the French PharmacoVigilance Database (FPVD). Cases were reports of memory loss in the FPVD between January 2000 and December 2009. Noncases were all other reports during the same period. To assess the association between memory impairment and drug intake, we calculated an odds ratio with its 95% confidence interval.
resultsAmong the 188,284 adverse drug reactions recorded, we identified 519 cases of memory loss. The sex ratio was 0.6 and the median age was 54 years (range 4-93). The maximal number of cases occurred between 40-49 and 50-59 years. Evolution was favourable in 63% of the cases. We found significant odds ratios for benzodiazepines (alprazolam, bromazepam, prazepam, clonazepam etc.), benzodiazepine-like hypnotics (zolpidem and zopiclone), antidepressants (fluoxetine, paroxetine and venlafaxine), analgesics (morphine, nefopam and tramadol), anticonvulsants (topiramate, pregabalin, levetiracetam etc.), antipsychotics (aripiprazole and lithium) and other drugs, such as trihexyphenidyl, ciclosporin and isotretinoin.
conclusionsOur study confirmed an association between memory disorders and some drugs, such as benzodiazepines and anticonvulsants. However, other drugs, such as benzodiazepine-like hypnotics, newer anticonvulsants, serotonin reuptake inhibitor antidepressants, isotretinoin and ciclosporin were significantly associated with memory disorders, although this was not described or poorly described in the literature. Taking account of the limits of this study in the FPVD (under-reporting, notoriety bias etc.), the case/noncase method allows assessment and detection of associations between exposure to drugs and a specific adverse drug reaction, such as memory disorders, and could thus generate signals and orientate us to further prospective studies to confirm such associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.